Share and Share Alike

The biotech industry is important for the creation of new drugs, job growth, and the health of the overall economy, but companies in this sector have continually found it challenging to raise the money they need to operate, says biopharmaceutical investment professional Mark Kessel in The Scientist. One solution, he says, would be for big pharma to create a biotech fund that utilizes pharma's cash to support biotech where needed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.